Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma

被引:14
作者
Ababneh, Hazim S. [1 ]
Ng, Andrea K. [2 ]
Abramson, Jeremy S. [3 ]
Soumerai, Jacob D. [3 ]
Takvorian, Ronald W. [3 ]
Frigault, Matthew J. [3 ]
Patel, Chirayu G. [1 ,4 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA USA
[4] MGH Radiat Oncol, 55 Fruit St,Cox 3, Boston, MA 02114 USA
关键词
CAR T-cell therapy; PET parameters; R/R LBCL; TOTAL LESION GLYCOLYSIS; TUMOR VOLUME; PROGNOSTIC VALUE; PET/CT; TOMOGRAPHY; DIAGNOSIS; OUTCOMES; BURDEN;
D O I
10.1002/hon.3231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) parameters on the CAR T-related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre- and post-CAR T metabolic parameters on survival and toxicities following CAR T-cell therapy. Fifty-nine patients with PET/CT scans done pre-and post-CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19-targeted CAR T-cell therapy. The median follow-up was 10.7 months [interquartile range (IQR): 2.6-25.5 months]. The overall response (complete response-CR and partial response) and CR rates post-CAR T were 76% (n = 45) and 53% (n = 31), respectively. On univariate analysis, low pre-CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post-CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post-CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre-CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre-CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre-CAR T was associated with grade 3-4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post-CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre-CAR T (HR = 2.4, p = 0.03), age >= 60 (HR = 2.7, p = 0.03), and bulky disease (>= 5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post-CAR T was identified as the most prognostic factor associated with inferior OS.
引用
收藏
页数:10
相关论文
共 30 条
[1]   Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy [J].
Ababneh, Hazim S. ;
Abramson, Jeremy S. ;
Johnson, P. Connor ;
Patel, Chirayu G. .
RADIOTHERAPY AND ONCOLOGY, 2022, 175 :65-72
[2]   Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].
Abramson, Jeremy S. ;
Palomba, M. Lia ;
Gordon, Leo I. ;
Lunning, Matthew A. ;
Wang, Michael ;
Arnason, Jon ;
Mehta, Amitkumar ;
Purev, Enkhtsetseg ;
Maloney, David G. ;
Andreadis, Charalambos ;
Sehgal, Alison ;
Solomon, Scott R. ;
Ghosh, Nilanjan ;
Albertson, Tina M. ;
Garcia, Jacob ;
Kostic, Ana ;
Mallaney, Mary ;
Ogasawara, Ken ;
Newhall, Kathryn ;
Kim, Yeonhee ;
Li, Daniel ;
Siddiqi, Tanya .
LANCET, 2020, 396 (10254) :839-852
[3]   Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma [J].
Bailly, Clement ;
Carlier, Thomas ;
Tessoulin, Benoit ;
Gastinne, Thomas ;
Kraeber-Bodere, Francoise ;
Le Gouill, Steven ;
Bodet-Milin, Caroline .
HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) :796-800
[4]   SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model [J].
Ceriani, Luca ;
Gritti, Giuseppe ;
Cascione, Luciano ;
Pirosa, Maria Cristina ;
Polino, Angela ;
Ruberto, Teresa ;
Stathis, Anastasios ;
Bruno, Andrea ;
Moccia, Alden A. ;
Giovanella, Luca ;
Hayoz, Stefanie ;
Schaer, Saemi ;
Dirnhofer, Stefan ;
Rambaldi, Alessandro ;
Martinelli, Giovanni ;
Mamot, Christoph ;
Zucca, Emanuele .
BLOOD ADVANCES, 2020, 4 (06) :1082-1092
[5]   Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma [J].
Ceriani, Luca ;
Martelli, Maurizio ;
Zinzani, Pier Luigi ;
Ferreri, Andres J. M. ;
Botto, Barbara ;
Stelitano, Caterina ;
Gotti, Manuel ;
Cabras, Maria Giuseppina ;
Rigacci, Luigi ;
Gargantini, Livio ;
Merli, Francesco ;
Pinotti, Graziella ;
Mannina, Donato ;
Luminari, Stefano ;
Stathis, Anastasios ;
Russo, Eleonora ;
Cavalli, Franco ;
Giovanella, Luca ;
Johnson, Peter W. M. ;
Zucca, Emanuele .
BLOOD, 2015, 126 (08) :950-956
[6]   Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial [J].
Cottereau, Anne-Segolene ;
Versari, Annibale ;
Loft, Annika ;
Casasnovas, Olivier ;
Bellei, Monica ;
Ricci, Romain ;
Bardet, Stephane ;
Castagnoli, Antonio ;
Brice, Pauline ;
Raemaekers, John ;
Deau, Benedicte ;
Fortpied, Catherine ;
Raveloarivahy, Tiana ;
Van Zele, Emelie ;
Chartier, Loic ;
Borght, Thierry Vander ;
Federico, Massimo ;
Hutchings, Martin ;
Ricardi, Umberto ;
Andre, Marc ;
Meignan, Michel .
BLOOD, 2018, 131 (13) :1456-1463
[7]   Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients [J].
Cottereau, Anne-Segolene ;
El-Galaly, Tarec Christoffer ;
Becker, Stephanie ;
Broussais, Florence ;
Petersen, Lars Jelstrup ;
Bonnet, Christophe ;
Prior, John O. ;
Tilly, Herve ;
Hutchings, Martin ;
Casasnovas, Olivier ;
Meignan, Michel .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) :589-595
[8]   Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma [J].
Cottereau, Anne-Segolene ;
Lanic, Helene ;
Mareschal, Sylvain ;
Meignan, Michel ;
Vera, Pierre ;
Tilly, Herve ;
Jardin, Fabrice ;
Becker, Stephanie .
CLINICAL CANCER RESEARCH, 2016, 22 (15) :3801-3809
[9]   High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma [J].
Dean, Erin A. ;
Mhaskar, Rahul S. ;
Lu, Hong ;
Mousa, Mina S. ;
Krivenko, Gabriel S. ;
Lazaryan, Aleksandr ;
Bachmeier, Christina A. ;
Chavez, Julio C. ;
Nishihori, Taiga ;
Davila, Marco L. ;
Khimani, Farhad ;
Liu, Hien D. ;
Pinilla-Ibarz, Javier ;
Shah, Bijal D. ;
Jain, Michael D. ;
Balagurunathan, Yoganand ;
Locke, Frederick L. .
BLOOD ADVANCES, 2020, 4 (14) :3268-3276
[10]   Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma [J].
Feng, Xiaoyan ;
Wen, Xin ;
Li, Ling ;
Sun, Zhenchang ;
Li, Xin ;
Zhang, Lei ;
Wu, Jingjing ;
Fu, Xiaorui ;
Wang, Xinhua ;
Yu, Hui ;
Ma, Xinran ;
Zhang, Xudong ;
Xie, Xinli ;
Han, Xingmin ;
Zhang, Mingzhi .
CANCER RESEARCH AND TREATMENT, 2021, 53 (03) :837-846